Efficacy of peripheral parenteral nutrition solution on outcomes in robotic pancreatoduodenectomy

Efficacy of peripheral parenteral nutrition solution on outcomes in robotic pancreatoduodenectomy: A randomized controlled trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1061260023

Enrollment

Registered

2026-05-21

Start date

2026-06-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The patients who require robotic pancreatoduodenectomy

Interventions

For postoperative fluid therapy, peripheral parenteral nutrition solution will be used

2200ml per a day from postoprative day 1. The dosage can be adjusted according to the amount of oral intake.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Age is 18 years or older 2.The patients who receive robotic pancreatoduodenectomy at our institution 3. Patients who have given written informed consent

Exclusion criteria

Exclusion criteria: 1. patients who cannot give consent 2. severe respiratory dysfunction (arterial PaO2 <70 mmHg) 3. severe cardiac dysfunction (New York Heart Association 3 or more) 4. severe hepatic dysfunction (Child Pugh classification C) 5. severe renal dysfunction (hemodialysis) 6. acute bacterial infections 7. severe psychiatric disorder 8. patients with distant metastases 9. palliative surgery 10. emergency surgery 11. investigator not available

Design outcomes

Primary

Measure	Time frame
Body weight loss rate on postoperative 1 month compared t admission	—

Secondary

Measure	Time frame
Muscle mass reduction rate before discharge Body composition changes before discharge Changes of skeletal muscle mass, weight loss rate, body composition on postoperative 1 month Nutrition-related blood index (TP, Alb, pre-Alb, T-Chol, lymphocyte count, CRP) Inflammatory reaction increased (postoperative maximum values of WBC and CRP) Postoperative outcomes (length of hospital stay, complications, etc) Postoperative liver and renal dysfunction (AST, ALT, T-Bil, BUN, Cr) Postoperative QOL evaluation (PGSAS-45) peripheral parenteral nutrition solution dosage during observation period	—

Measure

Time frame

Muscle mass reduction rate before discharge Body composition changes before discharge Changes of skeletal muscle mass, weight loss rate, body composition on postoperative 1 month Nutrition-related blood index (TP, Alb, pre-Alb, T-Chol, lymphocyte count, CRP) Inflammatory reaction increased (postoperative maximum values of WBC and CRP) Postoperative outcomes (length of hospital stay, complications, etc) Postoperative liver and renal dysfunction (AST, ALT, T-Bil, BUN, Cr) Postoperative QOL evaluation (PGSAS-45) peripheral parenteral nutrition solution dosage during observation period

—

Contacts

Public ContactKosei Takagi

Okayama University Hospital

kosei0913@gmail.com+81-86-235-7257

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026